Ludwig Enterprises announced that the Company has filed a patent on proprietary technology, the "Ludwig mRNA Inflammatory Index™." The patent covers the application of messenger ribonucleic acid (mRNA) in diagnosing, managing, and evaluating inflammatory disease patient treatment response in heart disease, diabetes, autoimmune disease, preeclampsia, and bladder, colon, and breast cancer. The molecule mRNA carries genetic information needed to produce proteins by cells. Because the data in DNA cannot be decoded directly into proteins, it is first transcribed or copied into mRNA.

Each molecule of mRNA encodes the information for one protein. The mRNA molecules are transported through a cell's outer envelope into the cytoplasm, where they are translated by the rRNA of ribosomes, cellular structures which perform biological protein synthesis. Specific amounts of amino acids in a protein and their sequence determine the protein's unique properties; for example, muscle protein and hair protein contain the same 20 amino acids, but the sequences of these amino acids in the two proteins are quite different.

Segments of mRNA are like a written message, and these "words" are translated into specific amino acids that make up protein. An example is mRNA vaccines that teach our cells how to make a protein that will trigger an immune response inside our bodies. Like all vaccines, mRNA vaccines benefit people who get vaccinated by protecting against diseases like COVID-19 without risking the potentially severe consequences of getting sick.

The Ludwig mRNA Inflammatory Index™ will be used in the recent announcement: "Ludwig Enterprises and Emerson Urology Associates Plan Bladder Cancer BCG Immunotherapy Study. Clinically, high-risk non-muscle-invasive bladder cancer (NMIBC) is treated with adjuvant intravesical instillations of Bacillus Calmette-Guérin (BCG) after surgery to eradicate residual disease and hence reduce the frequency of recurrence and progression (Babjuk, 2017; Lindskrog, 2021). The Ludwig proprietary "Index" has the potential to create a genetic signature in patients with bladder cancer.

This genetic signature provides a potential framework in bladder cancer clinical trials to optimize early diagnosis and clinical management with anticancer therapy. The market for this advanced early detection system is also virtually untapped, with little competition in the billion-dollar healthcare industry. Ludwig can use these cutting-edge technologies to help people live longer, healthier lives by providing sensitive testing methods that have the potential to detect genetic markers of inflammation in diseases, such as heart disease or cancer, before there are obvious symptoms. Doctors can potentially monitor and modify a patient's positive or negative response in the treatment process - potentially saving billions in chronic disease healthcare costs.